X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome X4 Pharmaceuticals (Nasdaq: XFOR) announced the EMA CHMP has issued a positive opinion recommending marketing authorization under exceptional circumstances for mavorixafor (XOLREMDI) to treat WHIM syndrome in the EU. The European Commission is expected to issue a final decision in Q2 2026.CHMP support is based on the Phase 3 4WHIM trial showing statistically significant increases in ANC and ALC thresholds, ~40% reduction in total infection score, and a 60% reduction in annualized infection rate versus placebo. X4 has a commercialization license with Norgine and may receive up to €226 million plus escalating royalties.

#XFOR X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering X4 Pharmaceuticals (Nasdaq: XFOR) commenced an underwritten public offering on October 23, 2025 of shares of common stock or, for certain investors, pre-funded warrants to purchase common stock. The company expects to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities. The offering is subject to market and other conditions and may not be completed.Use of proceeds is stated as funding the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, plus general and administrative expenses, capital expenditures, working capital and other corporate purposes. Leerink Partners, Stifel and Guggenheim are joint bookrunning managers. A shelf registration became effective on August 24, 2023.

#XFOR X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

Most searched small-cap stocks, Wed Aug 13th - #UPXI #ALTS #RSLS #XFOR #ATNF #RXRX #ONDS #OPEN #FUBO #BSLK #ZKIN #WBTN #SPNS #UWMC #TWST #TLRY #SBET #OBE #MNTS #MAG - More: crystalequityresearch.com/most-searche... - #smallcap

🚀 Exciting times for #XFOR! With a $60M boost and new leadership, momentum is strong. Current price: $3.17. RSI hints at pullbacks, but MACD shows bullish vibes. Consider going LONG at $3.10, targeting $3.50 & $3.80. Stay sharp on market trends! 📈 #FeetrAI #Stocks

🚀 Exciting times for #XFOR! After a $60M boost and leadership shake-up, the stock's up to $3.13 with high volume! 📈 RSI hints at overbought, but MACD stays bullish. Consider entry at $3.10, target $3.50 & $3.80. Stop loss: $2.90. Stay sharp, volatility ahead! #FeetrAI

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership X4 Pharmaceuticals (NASDAQ: XFOR) has announced a significant $60 million PIPE financing led by Coastlands Capital, with support from Bain Capital Life Sciences and NEA. The financing involves issuing 11,040,776 shares of common stock at $1.42 per share and pre-funded warrants for up to 31,234,731 shares.Concurrent with the financing, X4 has undergone major leadership changes. Dr. Adam Craig has been appointed as Executive Chairman, John Volpone as President, and David Kirske as CFO, replacing former CEO Paula Ragan and CFO Adam Mostafa. The new management team, previously from CTI BioPharma, brings extensive experience in operational turnarounds and life sciences.The proceeds will support the development of mavorixafor for chronic neutropenia treatment and its commercialization for WHIM syndrome. The company's Phase 3 4WARD study is currently ongoing.

#XFOR X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) X4 Pharmaceuticals (XFOR) presented positive Phase 2 trial data for mavorixafor in treating chronic neutropenia at the 30th EHA Congress. The 6-month study involving 23 participants demonstrated that oral, once-daily mavorixafor effectively increased absolute neutrophil count (ANC) both as monotherapy and in combination with G-CSF. Key findings showed that patients with severe chronic neutropenia achieved nearly 3-fold increases in mean ANC levels, and 89% of participants were able to reduce or discontinue injectable G-CSF while maintaining normal ANC levels. The drug was well-tolerated with no drug-related serious adverse events. A sub-study revealed that treated patients' functional neutrophil levels were comparable to healthy donors. The company is currently conducting a global Phase 3 pivotal trial, expected to complete enrollment in Q3/Q4 2025.

#XFOR X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

FDA Fast Track: X4 Pharmaceuticals New Oral Drug Could Replace Painful Injections for Chronic Neutropenia X4's oral drug mavorixafor advances with FDA Fast Track status for chronic neutropenia treatment, offering alternative to injectable therapies. See trial timeline.

#XFOR X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

Small-cap stocks with bullish Moving Average Convergence Divergence Crossovers, Mon May 12th - #LGO #NEO #OCSL #PRPH #QTTB #RBBN #TIL #ULH #VRCA #XFOR #WTF #GRRR #DMLP #CCB #BLMN #ALAR #WSR #WNC #RVLV #HLLY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates X4 Pharmaceuticals (XFOR) reported Q1 2025 financial results and corporate updates. The company's 4WARD Phase 3 trial for chronic neutropenia is progressing well, with full enrollment expected in Q3/Q4 2025 and top-line data in 2H 2026. X4 reported net revenue of $28.8 million, including $27.9 million from the Norgine agreement and $0.9 million from XOLREMDI product sales. Since its May 2024 launch, XOLREMDI has generated $3.5 million in U.S. sales. The company ended Q1 with $87.7 million in cash, sufficient to fund operations into 1H 2026. Key developments include EMA acceptance of mavorixafor's MAA for WHIM syndrome, new international partnerships with Norgine Pharma UK and taiba rare, and a strategic restructuring expected to reduce annual spending by $30-35 million. The company recently completed a 1-for-30 reverse stock split.

#XFOR X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

Just In: ( NASDAQ: #XFOR ) X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Announces Reverse Stock Split X4 Pharmaceuticals (XFOR) has announced a 1-for-30 reverse stock split effective April 28, 2025. The split will reduce outstanding shares from approximately 173.6 million to 5.8 million, with trading on Nasdaq Capital Market beginning on the same date.This strategic move comes after receiving a Nasdaq deficiency notice on August 13, 2024, due to the stock price falling below the required $1.00 minimum bid for 30 consecutive business days. While X4 received an additional compliance period until August 11, 2025, the reverse split aims to increase the stock price and maintain Nasdaq listing requirements.The split will proportionally adjust equity incentive plans, stock options, and warrants. Stockholders with fractional shares will receive cash in lieu, and those with book-entry shares will see changes reflected in their accounts after April 28, 2025.

#XFOR X4 Pharmaceuticals Announces Reverse Stock Split

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

#XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25… buff.ly/Albvjwg

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update X4 Pharmaceuticals (XFOR) reported its Q4 and full year 2024 financial results, highlighting significant progress in commercializing XOLREMDI® for WHIM syndrome and advancing clinical trials. Key financial metrics include $2.6 million in XOLREMDI® net revenues since its May 2024 launch, and $102.8 million in cash position as of December 31, 2024.The company's Phase 3 4WARD trial for chronic neutropenia has reached ~90% site activation, with full enrollment expected in Q3/Q4 2025 and top-line data anticipated in 2H 2026. Notable achievements include the sale of a priority review voucher for $105 million and strategic partnerships in EU/ANZ and MENA regions, with Norgine Pharma providing a €28.5 million upfront payment.Financial results show R&D expenses of $81.6 million and SG&A expenses of $61.5 million for 2024. The company implemented a strategic restructuring in February 2025, expected to reduce annual spending by $30-35 million. X4 projects sufficient funding into first half of 2026.

#XFOR X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

Curious which #pennystock insiders have been purchasing recently?

#ZEOX #RCG #USEG #CASK #MMLP #XFOR #stockmarket #insidealert

X4 Pharma's Major Restructuring: 43 Jobs Cut as Company Pivots to Core Drug Development X4 Pharmaceuticals implements strategic overhaul, reducing workforce by 30% and closing Vienna facility to extend cash runway through 2026. Company refocuses on mavorixafor development.

#XFOR X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

X4's WHIM Syndrome Drug XOLREMDI Advances in Europe After FDA Approval Success X4 Pharmaceuticals' mavorixafor gains EMA validation for WHIM syndrome review following US approval. Could become Europe's first treatment for rare immunodeficiency disorder.

#XFOR X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

X4 Pharma Lands €28.5M Upfront in Major European Licensing Deal for WHIM Treatment X4 Pharmaceuticals partners with Norgine in exclusive €254.5M deal for mavorixafor commercialization across Europe & ANZ, including double-digit royalties on future sales.

#XFOR X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VRTX, #GEVO, #SEE, #XFOR, #BEEM

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#XFOR, #SEE, #VNET, #RBA, #HRL

#OptionFlow #OptionsTrading #Trading

#XFOR X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

News; ( NASDAQ: #XFOR ) X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

#StockMarket #News

#XFOR X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

www.stocktitan.net/news/XFOR/x4-pharmaceuti...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#LULU, #FRSH, #AGTI, #INVZ, #XFOR

#OptionFlow #OptionsTrading #Trading